48 results  1 of 3 

1 Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis
Ting Xu, Xicheng Wang, Ying Xin, Zhenghang Wang, Jifang Gong, Xiaotian Zhang, Yanyan Li, Congcong Ji, Yu Sun, Feilong Zhao, Depei Huang, Yuezong Bai, Jian Li, Lin Shen
Cancer Res Treat.2023;55(2):626-635.   Published online 2022 December 23     DOI: http://dx.doi.org/10.4143/crt.2022.1058
      
2 Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
Beung-Chul Ahn, Ye-Jeong Han, Hye Ryun Kim, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
Cancer Res Treat.2023;55(2):488-497.   Published online 2022 November 9     DOI: http://dx.doi.org/10.4143/crt.2022.359
      
3 PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
Cancer Res Treat.2023;55(2):531-541.   Published online 2022 September 7     DOI: http://dx.doi.org/10.4143/crt.2022.221
      
4 Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
Yong-Pyo Lee, Min-Sang Lee, HongSik Kim, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Cancer Res Treat.2022;54(4):1130-1137.   Published online 2022 January 17     DOI: http://dx.doi.org/10.4143/crt.2021.1103
      
5 Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
Ji-Yeon Kim, Seok Jin Nam, Jeong Eon Lee, Jonghan Yu, Byung Joo Chae, Se Kyung Lee, Jai Min Ryu, Jin Seok Ahn, Young-Hyuck Im, Seok Won Kim, Yeon Hee Park
Cancer Res Treat.2022;54(4):1091-1098.   Published online 2022 January 10     DOI: http://dx.doi.org/10.4143/crt.2021.901
      
6 Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens
Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas
Cancer Res Treat.2022;54(4):1053-1064.   Published online 2021 November 17     DOI: http://dx.doi.org/10.4143/crt.2021.748
      
7 Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
Kyung-Hun Lee, Joohyuk Sohn, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Seock-Ah Im, Sung-Bae Kim
Cancer Res Treat.2021;53(4):1084-1095.   Published online 2021 March 24     DOI: http://dx.doi.org/10.4143/crt.2020.1381
      
8 New Molecular Targeted Therapy of Metastatic Colorectal Cancer
Jungmin Jo
Ewha Med J.2021;44(1):11-18.   Published online 2021 January 31     DOI: http://dx.doi.org/10.12771/emj.2021.44.1.11
      
9 Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu
Cancer Res Treat.2020;52(4):1059-1066.   Published online 2020 April 24     DOI: http://dx.doi.org/10.4143/crt.2019.633
      
10 HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation
Soomin Ahn, Ji Won Woo, Kyoungyul Lee, So Yeon Park
J Pathol Transl Med.2020;54(1):34-44.   Published online 2019 November 6     DOI: http://dx.doi.org/10.4132/jptm.2019.11.03
      
11 Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Kangkook Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.2020;52(1):292-300.   Published online 2019 July 26     DOI: http://dx.doi.org/10.4143/crt.2019.186
      
12 BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy
Sung-Bae Kim, In-Gu Do, Janice Tsang, Tae-You Kim, Yoon-Sim Yap, Gerardo Cornelio, Gyungyub Gong, Soonmyung Paik, Suee Lee, Ting-Ying Ng, Sarah Park, Ho-Suk Oh, Joanne Chiu, Joohyuk Sohn, Moonhee Lee, Young-Jin Choi, Eun Mi Lee, Kyong-Hwa Park, Christos Nathaniel, Jungsil Ro
Cancer Res Treat.2019;51(4):1527-1539.   Published online 2019 June 4     DOI: http://dx.doi.org/10.4143/crt.2018.598
      
13 Induction of Melanoma Cell-Selective Apoptosis Using Anti-HER2 Antibody-Conjugated Gold Nanoparticles
Hyeon Jun Jeon, Byul Bo Ra Choi, Kwang Ha Park, Dae Seok Hwang, Uk Kyu Kim, Gyoo Cheon Kim
Yonsei Med J.2019;60(6):509-516.   Published online 2019 May 22     DOI: http://dx.doi.org/10.3349/ymj.2019.60.6.509
      
14 Serous Adenocarcinoma of Fallopian Tubes: Histological and Immunohistochemical Aspects
Natalia Hyriavenko, Mykola Lyndin, Kateryna Sikora, Artem Piddubnyi, Ludmila Karpenko, Olha Kravtsova, Dmytrii Hyriavenko, Olena Diachenko, Vladyslav Sikora, Anatolii Romaniuk
J Pathol Transl Med.2019;53(4):236-243.   Published online 2019 April 11     DOI: http://dx.doi.org/10.4132/jptm.2019.03.21
      
15 Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma
Amany Salama, Mohammad Arafa, Eman ElZahaf, Abdelhadi Mohamed Shebl, Azmy Abd El-Hameed Awad, Sylvia A. Ashamallah, Reda Hemida, Anas Gamal, Abd AlRahman Foda, Khaled Zalata, El-Said M. Abdel-Hady
J Pathol Transl Med.2019;53(3):164-172.   Published online 2019 February 28     DOI: http://dx.doi.org/10.4132/jptm.2019.02.12
      
16 Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
Cheol Kyu Park, Jae Young Hur, Chang-Min Choi, Tae-Ok Kim, Hyun-Ju Cho, Hong-Joon Shin, Jung-Hwan Lim, Yoo-Duk Choi, Young-Chul Kim, In-Jae Oh
J Korean Med Sci.2018;33(1):e7.  Published online 2017 November 10     DOI: http://dx.doi.org/10.3346/jkms.2018.33.e7
      
17 Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang
Cancer Res Treat.2018;50(3):835-842.   Published online 2017 August 29     DOI: http://dx.doi.org/10.4143/crt.2017.303
      
18 Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics
Jeong Sub Lee, Se Hyung Kim, Seock-Ah Im, Min A Kim, Joon Koo Han
Korean J Radiol.2017;18(5):809-820.   Published online 2017 July 17     DOI: http://dx.doi.org/10.3348/kjr.2017.18.5.809
      
19 HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
Dang Anh Thu Phan, Vu Thien Nguyen, Thi Ngoc Ha Hua, Quoc Dat Ngo, Thi Phuong Thao Doan, Sao Trung Nguyen, Anh Tu Thai, Van Thanh Nguyen
J Pathol Transl Med.2017;51(4):396-402.   Published online 2017 June 19     DOI: http://dx.doi.org/10.4132/jptm.2017.04.24
      
20 Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
Gilhyang Kim, Yul Ri Chung, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med.2016;50(6):436-441.   Published online 2016 October 10     DOI: http://dx.doi.org/10.4132/jptm.2016.07.12
      

 1 of 3